LeMaitre Vascular (NASDAQ:LMAT) Issues Q2 Earnings Guidance

LeMaitre Vascular (NASDAQ:LMAT) updated its second quarter earnings guidance on Thursday. The company provided EPS guidance of $0.45-0.50 for the period, compared to the consensus EPS estimate of $0.44. The company issued revenue guidance of $53.7-56.1 million, compared to the consensus revenue estimate of $54.29 million. LeMaitre Vascular also updated its FY24 guidance to $1.73-1.84 EPS.

Analyst Ratings Changes

Several equities analysts recently issued reports on the stock. StockNews.com raised shares of LeMaitre Vascular from a hold rating to a buy rating in a report on Friday. JMP Securities lifted their price objective on shares of LeMaitre Vascular from $72.00 to $77.00 and gave the company a market outperform rating in a report on Friday. KeyCorp assumed coverage on shares of LeMaitre Vascular in a report on Tuesday, February 6th. They set a sector weight rating on the stock. Stifel Nicolaus raised shares of LeMaitre Vascular from a hold rating to a buy rating and lifted their price objective for the company from $59.00 to $75.00 in a report on Friday, April 26th. Finally, Barrington Research lifted their price objective on shares of LeMaitre Vascular from $69.00 to $79.00 and gave the company an outperform rating in a report on Friday. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of Moderate Buy and a consensus target price of $73.83.

LeMaitre Vascular Trading Up 11.2 %

Shares of LeMaitre Vascular stock traded up $7.45 during trading hours on Friday, reaching $74.22. The stock had a trading volume of 329,984 shares, compared to its average volume of 110,751. The stock’s 50 day moving average is $65.93 and its 200 day moving average is $58.85. The firm has a market capitalization of $1.67 billion, a PE ratio of 49.15, a PEG ratio of 3.20 and a beta of 0.88. LeMaitre Vascular has a twelve month low of $44.27 and a twelve month high of $74.64.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings data on Thursday, May 2nd. The medical instruments supplier reported $0.44 earnings per share for the quarter, topping analysts’ consensus estimates of $0.39 by $0.05. The business had revenue of $53.48 million during the quarter, compared to the consensus estimate of $51.50 million. LeMaitre Vascular had a net margin of 16.99% and a return on equity of 11.75%. The company’s revenue was up 13.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.27 earnings per share. As a group, sell-side analysts predict that LeMaitre Vascular will post 1.77 earnings per share for the current year.

LeMaitre Vascular Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, May 30th. Investors of record on Thursday, May 16th will be given a dividend of $0.16 per share. The ex-dividend date is Wednesday, May 15th. This represents a $0.64 annualized dividend and a dividend yield of 0.86%. LeMaitre Vascular’s dividend payout ratio (DPR) is presently 42.38%.

Insider Buying and Selling

In related news, Director John A. Roush sold 7,500 shares of the company’s stock in a transaction dated Thursday, March 7th. The shares were sold at an average price of $69.00, for a total transaction of $517,500.00. Following the completion of the sale, the director now owns 2,278 shares of the company’s stock, valued at approximately $157,182. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In related news, Director John A. Roush sold 7,500 shares of the company’s stock in a transaction dated Thursday, March 7th. The shares were sold at an average price of $69.00, for a total transaction of $517,500.00. Following the completion of the sale, the director now owns 2,278 shares of the company’s stock, valued at approximately $157,182. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Lawrence J. Jasinski sold 5,110 shares of the company’s stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $67.50, for a total transaction of $344,925.00. Following the sale, the director now directly owns 5,309 shares of the company’s stock, valued at approximately $358,357.50. The disclosure for this sale can be found here. Insiders sold a total of 114,036 shares of company stock worth $7,873,749 in the last 90 days. Insiders own 10.79% of the company’s stock.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.